Supplementary Data1 from A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer

Filipa C. Lynce; Noah Graham; Bose S. Kochupurakkal; Huy Nguyen; Brittany Bychkovsky; Philip Daniel Poorvu; Victoria Attaya; Raechel Davis; Molly K. DiLullo; Alan D. D’Andrea; Judy Ellen Garber; Kavita Garg; Lee P. Lim; Mark Li; Cloud Peter Paweletz; Nabihah Tayob; Geoffrey Ira Shapiro; Sara M. Tolaney

doi:10.1158/1078-0432.31248718

Supplementary Data1 from A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer

2026 Open access

Read full text

Authors: Filipa C. Lynce, Noah Graham, Bose S. Kochupurakkal, Huy Nguyen, Brittany Bychkovsky, Philip Daniel Poorvu, Victoria Attaya, Raechel Davis, Molly K. DiLullo, Alan D. D’Andrea, Judy Ellen Garber, Kavita Garg

+6 more

Lee P. Lim, Mark Li, Cloud Peter Paweletz, Nabihah Tayob, Geoffrey Ira Shapiro, Sara M. Tolaney

DOI: 10.1158/1078-0432.31248718

Cited by: 0

Abstract

Supplementary Tables S1-S7 Supplementary Figures S1-S2

Fields of Study & Subjects

PARP inhibition in cancer therapy BRCA gene mutations in cancer Advanced Breast Cancer Therapies

Publication details

Publication date: 4 February 2026